Table 2.
Demographic, clinical, and surgery-related variables, per phenotype
| Demographical and clinical variables | Total | Phenotype at end of follow-up | |||
| B2 (n = 29, 28%) | B3 (n = 74, 72%) | Pa | |||
| Gender, n (%) | 0.390 | ||||
| Female | 46 (45) | 11 (38) | 35 (47) | ||
| Male | 57 (55) | 18 (62) | 39 (53) | ||
| Age at diagnosis, n (%) | 0.021 | ||||
| A1: ≤16 yr old | 11 (11) | 1 (3) | 10 (14) | ||
| A2: 17–40 yr old | 70 (68) | 17 (59) | 53 (72) | ||
| A3: >40 yr old | 22 (21) | 11 (38) | 11 (15) | ||
| Phenotype at diagnosis, n (%) | <0.001 | ||||
| B1: nonstricturing, nonpenetrating | 10 (10) | 1 (3) | 9 (12) | ||
| B2: stricturing | 37 (36) | 28 (97) | 9 (12) | ||
| B3: penetrating | 56 (54) | 0 (0) | 56 (76) | ||
| CD localization, n (%) | 0.002 | ||||
| L1 | 58 (56) | 18 (62) | 40 (54) | ||
| L1+L4 | 8 (8) | 6 (21) | 2 (3) | ||
| L3 | 32 (31) | 3 (10) | 29 (39) | ||
| L3+L4 | 5 (5) | 2 (7) | 3 (4) | ||
| Perianal disease, n (%) | 25 (24) | 5 (17) | 20 (27) | 0.324 | |
| Age at diagnosis, yr, mean (SD) | 30 (12) | 35 (13) | 28 (10) | 0.001b | |
| Total follow-up, yr, median (P25–P75) | 10 (7–12) | 12 (7–14) | 10 (7–12) | 0.024c | |
| Surgery-related variables | |||||
| Motif for first ileal surgery, n (%) | <0.001 | ||||
| Fistula/abscess | 66 (64) | 0 (0) | 66 (89) | ||
| Perforation | 5 (5) | 0 (0) | 5 (7) | ||
| Obstruction | 32 (31) | 29 (100) | 3 (4) | ||
| First ileal surgery, n (%) | >0.999 | ||||
| Segmental enterectomy | 7 (7) | 2 (7) | 5 (7) | ||
| Ileocecal resection | 86 (83) | 24 (83) | 62 (84) | ||
| Right hemicolectomy | 10 (10) | 3 (10) | 7 (9) | ||
| Motif of reoperation, n (%) | 0.050 | ||||
| Abscess | 3 (30) | 0 (0) | 3 (42) | ||
| Stricture (primary) | 4 (40) | 3 (100) | 1 (14) | ||
| Stricture (anastomotic) | 3 (30) | 0 (0) | 3 (43) | ||
| Preoperative therapy, n (%) | |||||
| 5-aminosalicylic acid | 49 (48) | 15 (52) | 34 (46) | 0.664 | |
| Steroids | 70 (68) | 23 (79) | 47 (64) | 0.122 | |
| Immunosuppressives | 60 (58) | 16 (55) | 44 (60) | 0.692 | |
| Anti-tumor necrosis factor alphad | 27 (26) | 6 (21) | 21 (28) | 0.468 | |
| Postoperative therapy, n (%) | |||||
| 5-aminosalicylic acid | 31 (30) | 11 (38) | 20 (27) | 0.278 | |
| Steroids | 32 (31) | 14 (48) | 18 (24) | 0.018 | |
| Immunosuppressives | 90 (87) | 27 (93) | 63 (85) | 0.342 | |
| Anti-tumor necrosis factor alphae | 61 (59) | 18 (62) | 43 (58) | 0.713 | |
| Other biologicsf | 11 (11) | 4 (14) | 7 (10) | 0.724 | |
| Post-re-operative therapy (n = 10), n (%) | |||||
| 5-aminosalicylic acid | 2 (20) | 1 (33) | 1 (14) | >0.999 | |
| Immunosuppressives | 7 (70) | 3 (100) | 4 (57) | 0.475 | |
| Anti-tumor necrosis factor alphag | 8 (80) | 2 (67) | 6 (86) | >0.999 | |
| Other biologicsh | 1 (10) | 1 (33) | 0 (0) | 0.300 | |
| Age at index surgery, yr, mean (SD) | 34 (13) | 40 (15) | 32 (11) | 0.008b | |
| Time from diagnosis to index surgery, yr, median (P25–P75) | 2.0 (0.5–6.0) | 3.0 (1.0–6.0) | 2.0 (0.5–6.0) | 0.273c | |
Bold entries indicate significant P values (P < 0.05).
CD, Crohn's disease; L1, terminal ileum; L1+L4, terminal ileum + upper gastrointestinal tract; L3, ileum and colon; L3+L4, ileocolonic + upper gastrointestinal tract.
a
χ2 test.
b
t test for independent samples.
c
Mann-Whitney test.
d
Infliximab (n = 22) and adalimumab (n = 2).
e
Infliximab (n = 51) and adalimumab (n = 10).
f
Vedolizumab (n = 7) and ustekinumab (n = 4).
g
Infliximab (n = 7) and adalimumab (n = 1).
h
Vedolizumab (n = 1).